جستجوی استاد راهنمای دانشگاهی

Caetano Reis e Sousa is a Professor of Immunology at Imperial College London and Senior Group Leader/Assistant Research Director at the Francis Crick Institute. He leads the Immunobiology Laboratory, focusing on dendritic cell biology, immune responses to pathogens, and cancer immunotherapy. His research explores how dendritic cells detect pathogens and dying cells, triggering adaptive immunity. Key roles include investigating cross-presentation mechanisms, C-type lectin receptors (e.g., DNGR-1), and vaccine development strategies. Education: BSc (Hons) Biology from Imperial College London (1989), DPhil in Immunology from University of Oxford (1992). Postdoctoral training at NIH under Ron Germain. Career milestones include founding the Immunobiology Lab at CRUK London Research Institute (1998–2015) before joining the Crick. Awards & Recognition: Highly Cited Researcher (Thomson Reuters), BD Biosciences Prize (2002), Liliane Bettencourt Award (2008), Louis-Jeantet Prize (2017), Fellowships at Royal Society (2019), Academy of Medical Sciences (2006), and EMBO (2006). Named Officer of the Order of Sant'Iago da Espada (Portugal, 2009). Research Themes: Dendritic cell activation pathways, cross-presentation of tumor antigens, microbiome-cancer immunity links, and immune evasion mechanisms. Collaborations involve institutions like UCL, King's College London, and global health networks. Labs/Teams: Head of Immunobiology Lab at Crick, with expertise in immunology, cell biology, and virology. Facilities include Flow Cytometry, Genomics, and Light Microscopy cores. Active in pandemic response (e.g., SARS-CoV-2 testing initiatives).

• Immunology
• Infectious Disease
• Cancer Immunotherapy
• +۳ مورد دیگر

Dr. Alanna (Leni) Green is a Senior Research Fellow at the School of Medicine and Population Health, University of Sheffield. She leads the Cancer and Bone (CAB) Lab, focusing on eradicating chemotherapy-resistant dormant cancer cells in bone. Her academic journey includes a BBiomedSci at Monash University, a PhD at the University of Melbourne, and postdoctoral roles in the Sheffield Myeloma Research Team and Helleday’s lab. Education: BBiomedSci (Hons), Monash University PhD, University of Melbourne Her research explores bone-immune-cancer interactions, particularly how bone microenvironment cells protect tumors from therapy. Key areas include retinoic acid receptor signaling, vitamin A regulation of hematopoiesis, and novel drug development for myeloma and bone-metastatic cancers. Recent publications highlight her work in cancer metabolism (MTHFD2 inhibition), bone repair mechanisms, and microenvironmental regulation of lymphopoiesis. She has received over 20 awards, including Young Investigator Prizes from ECTS and ASBMR. Scientific Awards: Wellcome Trust Career Development Award (2024) Yorkshire Cancer Research Pioneer Advanced Fellowship (2024) Blood Cancer UK Project Grant (2023) Faculty MDH Early Career Researcher Prize (2020) Dr. Green supervises the Cancer and Bone Lab, which includes postdoctoral researchers and PhD students. She lectures on translational oncology and molecular medicine courses and actively contributes to professional societies like the Bone Research Society and ECTS.

• Bone-Immune-Cancer Interactions
• Cancer Dormancy
• Retinoic Acid Receptor Signaling
• +۳ مورد دیگر

Sarah Cartmell is a Professor of Bioengineering and Head of the Department of Materials at The University of Manchester. She holds senior roles in the School of Natural Sciences, including Senate membership and leadership in advanced materials initiatives like the Royce Institute. Her research focuses on biomaterials for regenerative medicine, including tendon repair, stem cell differentiation, and bioreactor design. Cartmell has secured over £34.7 million in grants, authored 70+ publications, and serves on editorial and review boards for journals like Science and Technology of Advanced Materials . Her work contributes to UN Sustainable Development Goals in health and innovation. Education : B.Eng (Materials Science with Clinical Engineering, University of Liverpool, 1996), Ph.D. (Clinical Engineering, University of Liverpool, 2000), Postdoc at GeorgiaTech, and academic roles at Keele University. Research Interests : Translation of novel tissue repair products, mechanical force effects on stem cells, and advanced biomaterials for bone and cartilage regeneration. Grants & Funding : £12.7M as lead PI and £22M as PI/Co-I across 22 sources (government, industry, charities). Awards : President of UK Tissue and Cell Engineering Society, IOM3 Fellow, and TERMIS EU council member. Leadership : Led the Royce Institute’s biomedical materials initiative, coordinating 200+ stakeholders, and chairs major international conferences in biomaterials and tissue engineering. Projects : Includes AMFaces (3D-printed facial prosthetics), biomaterials for regenerative medicine, and bioelectronics networks. Labs/Teams : Biomaterials Research Group, Manchester Bioelectronics Network, and advanced materials in medicine initiatives. Her research bridges clinical and industrial applications, emphasizing translational solutions for musculoskeletal disorders and regenerative therapies.

• Biomaterials Engineering
• Tissue Engineering
• Regenerative Medicine
• +۳ مورد دیگر

Claire Booth is Professor of Gene Therapy and Paediatric Immunology within the Infection, Immunity & Inflammation Department at University College London. Her work bridges cutting-edge gene therapy techniques with clinical applications for pediatric immunodeficiency disorders, focusing on translating laboratory discoveries into therapeutic interventions for rare genetic conditions. Education: Doctor of Philosophy, University College London (2012) Master of Science, University College London (2007) Bachelor of Medicine/Bachelor of Surgery, King's College London (2001) Professor Booth's research centers on gene therapy approaches for inborn errors of immunity, with particular expertise in lentiviral vector systems, hematopoietic stem cell gene therapy, and genome editing techniques. Her work addresses critical challenges in treating rare immunodeficiency disorders including X-linked SCID, Fanconi anemia, leukocyte adhesion deficiency, and CTLA4 insufficiency. She investigates both the mechanistic underpinnings of these disorders and the development of novel therapeutic strategies that can be translated to clinical practice. Analysis of her recent publications (2023-2024) reveals a strong focus on clinical translation of gene therapy approaches, with numerous phase 1/2 clinical trial results, methodological improvements in conditioning regimens, and exploration of novel targets for immunodeficiency disorders. Her work spans basic science investigations through to clinical implementation, with particular attention to safety profiles, immune reconstitution patterns, and long-term outcomes in pediatric patients. Professor Booth actively collaborates with international research groups and clinical networks, contributing to consensus guidelines for managing rare immunological conditions. Her research program addresses critical gaps in understanding how to effectively deliver gene therapies for rare diseases while navigating the complex challenges of commercialization and accessibility.

• Gene Therapy
• Paediatric Immunology
• Immunology
• +۴ مورد دیگر

Professor Martin Graves is Professor of Magnetic Resonance Physics at the University of Cambridge, holding appointments within the School of Clinical Medicine and Department of Radiology. Since 1996, he has led the MRI Physics group at Addenbrooke's Hospital in Cambridge and serves as Honorary Consultant Clinical Scientist for the NHS. His primary institutional affiliation is with the Cambridge Mathematics of Information in Healthcare (CMIH) Hub at the Centre for Mathematical Sciences. His research focuses on advanced magnetic resonance imaging techniques with particular emphasis on hyperpolarized carbon-13 MRI for metabolic imaging applications. Key research areas include cardiac imaging for myocardial infarction assessment, cancer metabolism studies in renal cell carcinoma and ovarian cancer, neuroimaging of brain metabolism, and development of quantitative MRI methodologies. His work bridges physics, clinical medicine, and computational analysis to address diagnostic challenges in cardiovascular disease, oncology, and neurology. Analysis of his recent publications (2021-2025) reveals strong trends in hyperpolarized pyruvate imaging for cancer treatment monitoring, radiomics for plaque vulnerability assessment, and technical innovations in zero echo-time MRI. His research consistently targets clinical translation of advanced MRI techniques, with substantial focus on quantitative biomarkers for early treatment response assessment. No scientific awards or honors are documented in the provided materials Graves maintains active clinical-academic integration through his NHS consultancy role while leading physics research within Cambridge's imaging infrastructure. His work demonstrates consistent collaboration across medical specialties including cardiology, oncology, and neurology, with emphasis on developing clinically viable quantitative imaging biomarkers. The CMIH Hub serves as his primary research platform for mathematical approaches to healthcare imaging challenges.

• Magnetic Resonance Physics
• Hyperpolarized Carbon-13 MRI
• Cardiac Imaging
• +۴ مورد دیگر

Professor Changhao Wu holds a position in Cell Physiology at the University of Surrey's School of Biosciences. Previously, he served as a Lecturer (1995-2000) and Senior Lecturer (2001-2008) at University College London's Department of Medicine and Institute of Urology. His research focuses on cellular physiology/pathophysiology, ageing, oxidative stress, inflammation, and environmental medicine. Key areas include excitable/non-excitable tissue biology, renal/epithelial dysfunction, and toxicological mechanisms. Recent work addresses trichloroethylene-induced immune injury, bisphenol A effects in obesity, and gastric cancer metastasis. He contributes to translational studies in heart slices and cancer outcomes. His publications span toxicology, oncology, and immunology, with a focus on molecular mechanisms and clinical implications. Research interests include: Cellular responses to environmental toxins (e.g., trichloroethylene, bisphenol A) Inflammatory pathways in renal and liver injury Metabolic dysfunction and obesity-related pathologies Cancer metastasis and therapeutic targets NADPH oxidase (Nox) signaling in urothelial dysfunction Publications highlight interdisciplinary approaches to toxicology, oncology, and immunology. His work bridges basic science and clinical applications, such as identifying novel drug effects on cardiac tissue and elucidating mechanisms of chemical-induced autoimmune responses. Collaborative studies include investigations into complement system dysregulation and miRNA roles in disease progression.

• Cell Physiology
• Pathophysiology
• Ageing and Health
• +۴ مورد دیگر

Professor Seth Coffelt is a leading researcher in cancer immunology at the University of Glasgow , affiliated with the School of Cancer Sciences and the Cancer Research UK Scotland Institute . His work focuses on the dual roles of immune cells in promoting and suppressing cancer metastasis, particularly in breast, pancreatic, and colorectal cancers. Research Interests: Coffelt investigates γδ T cells, their interactions within the tumor microenvironment, and how tumors manipulate immune cell behavior to facilitate metastasis. His lab aims to develop novel immunotherapies targeting metastatic lesions. Publications: His recent studies explore DOCK2 in colorectal cancer, β-catenin in colon cancer immune exclusion, and mechanisms of γδ T cell regulation in cancer. These works span immunology, oncology, and bioengineering disciplines. Scientific Awards: British Association for Cancer Research AstraZeneca Young Scientist Frank Rose Award Wellcome Trust Seed Award Marie Curie Intra-European Fellowship Exceptional Contribution Award Advising and Collaborations: He mentors PhD students like Federico Lupo and Febby Nurdiya Ningsih , and collaborates globally on projects involving immune dynamics and cancer.

• Cancer Immunology
• Metastasis
• γδ T Cells
• +۴ مورد دیگر

Maria Cascio is a Research Fellow at the University of Aberdeen, currently serving as Senior Equality, Diversity and Inclusion Partner within the Directorate of People. She holds a PhD in Pharmaceutical Chemistry from the University of Fisciano, Salerno, Italy (2006) and has been based at the University of Aberdeen since 2007. Her academic journey includes significant research contributions in cannabinoid pharmacology and medicinal chemistry. PhD in Pharmaceutical Chemistry, 2006, University of Fisciano, Salerno, Italy Master in Chemistry and Pharmaceutical Technologies, 2002, University of Palermo, Italy Maria Cascio's primary research interests lie in the pharmacology and therapeutic potential of plant cannabinoids, with a focus on the endocannabinoid system in health and disease. Her work spans medicinal chemistry, allosteric modulation of cannabinoid receptors, and the development of novel CB1 and CB2 receptor ligands. She also investigates the anti-proliferative effects of omega-3 fatty acids and their derivatives in prostate cancer. Her research combines biochemical, pharmacological, and cell-based assays to characterize cannabinoid activity. Her recent publications reflect a strong trend in methodological development for cannabinoid receptor assays, pharmacological characterization of phytocannabinoids like THCV and CBD, and exploration of their therapeutic applications in inflammation, cancer, and neurological disorders. The work often involves interdisciplinary collaboration and synthetic chemistry approaches to probe receptor mechanisms. Maria Cascio is actively involved in university governance and inclusion initiatives, serving on multiple committees including the University Race Equality Strategy Group, the Equality, Diversity and Inclusion Committee, and as a Social Bias Observer in Promotions Committees. She has supervised both undergraduate and PhD students and has secured research funding from diverse sources including NIDA, NHS Grampian, Tenovus Scotland, and the University of Aberdeen. Her collaborations span institutions in the UK, Italy, and the US, reflecting the international scope of her research. She also contributes to the scientific community as a peer reviewer, book reviewer, and former Guest Associate Editor for Frontiers in Neuropharmacology. Maria Cascio leads and participates in several research teams focused on cannabinoid pharmacology, prostate cancer, diabetic nephropathy, anticonvulsant effects, and analgesia. Her work is supported by internal collaborators such as Dr Iain Brown, Professor Matteo Zanda, and Dr Mirela Delibegovic, and external partners across Europe and the United States.

• Medicinal Chemistry
• Pharmacology
• Cannabinoid Research
• +۷ مورد دیگر

Jan Rehwinkel is a Professor of Innate Immunology at the University of Oxford, where he leads an independent research group within the MRC Human Immunology Unit and the MRC Weatherall Institute of Molecular Medicine. His academic journey began with undergraduate training in biology at the University of Heidelberg, Germany, followed by doctoral studies at the European Molecular Biology Laboratory (EMBL). Rehwinkel's research focuses on the molecular mechanisms of host-pathogen interactions, particularly how cells detect virus infection through nucleic acid sensing by innate immune receptors. His work sits at the intersection of immunology, virology, and molecular biology, with specific emphasis on RNA biology in innate immunity. His laboratory investigates the roles of sensors like RIG-I and ZBP1/DAI in viral recognition, inflammatory cell death pathways, and immune responses to pathogens. Analysis of his recent publications reveals a consistent focus on nucleic acid sensing mechanisms, particularly the cGAS-STING pathway, Z-nucleic acid recognition, and viral immune evasion strategies. His work spans fundamental molecular mechanisms to translational applications in viral infections, autoinflammatory diseases, and cancer immunology. The research demonstrates strong interdisciplinary connections between innate immunity, cell death pathways, and viral pathogenesis. Rehwinkel's research program is supported by prestigious funding from the Medical Research Council (MRC), Wellcome Trust, Lister Institute, and European Union grants, reflecting the significance and impact of his work in immunology and virology. His laboratory, known as the Rehwinkel Group: Nucleic Acid Sensing, operates within the MRC Human Immunology Unit at the MRC Weatherall Institute of Molecular Medicine, contributing to Oxford's strong research environment in immunology and infectious diseases. The group employs molecular, cellular, and virological approaches to dissect the complex mechanisms of innate immune recognition.

• Immunology
• Virology
• Molecular Biology
• +۴ مورد دیگر

Professor Peter Giannoudis is a Clinical Professor at the University of Leeds School of Medicine and Honorary Consultant at Leeds General Infirmary, managing a major trauma unit serving 3.5 million people. He leads the Trauma & Orthopaedics section and heads clinical trials at LGI. His roles include Editor-in-Chief of Injury Journal and past leadership in global societies like the European Society of Pelvis and Acetabulum. Education: MD (2000, University of Leeds), trauma fellowships at University of Louisville (USA) and Hannover Medical School (Germany). Professional memberships span prestigious bodies like the Royal College of Surgeons and American College of Surgeons. Research focuses on bone regeneration, mesenchymal stem cells, and immune-inflammatory responses post-trauma. He has 600+ peer-reviewed papers (h-index 93, 32,567 citations), with key interests in fracture non-union biology, bioengineering, and implant evaluation. Collaborations include Leeds Institute of Rheumatic and Musculoskeletal Medicine and AO Foundation. Teaching involves postgraduate orthopaedic residents, trauma fellows, and AO fellows. Over 250 international lectures since 2004 highlight his global impact. Awards: FRCS, FACS, Injury Journal Editor-in-Chief (2010–present) Grants/Research: $2M+ in funded studies on biomaterials and fracture healing Labs/Teams: Regenerative Medicine Group, Orthopaedics and Trauma Sciences

• Bone Regeneration
• Fracture Fixation Complications
• Pelvic and Acetabulum Reconstruction
• +۳ مورد دیگر

Professor Stuart Rushworth is a faculty member at Norwich Medical School, University of East Anglia, where he serves as the scientific group leader for molecular haematology research. His work focuses on the tumour microenvironment in haematological malignancies, particularly Acute Myeloid Leukaemia and Multiple Myeloma, and the impact of infection and ageing on haematopoietic stem cells. Education: Bachelor's Degree – University of Sunderland PhD in Immunology – University of Cambridge Post-doctoral Training – University of Cambridge and University of East Anglia His research explores metabolic reprogramming, mitochondrial transfer, and stromal interactions in cancer. He has made significant contributions to understanding how leukaemia cells exploit the bone marrow microenvironment for survival and proliferation. His studies have identified key mechanisms such as fatty acid release from adipocytes and intercellular mitochondrial transfer via tunnelling nanotubes. His work bridges basic science and clinical translation, with implications for drug resistance and novel therapeutic strategies. The most recent articles highlight trends in immunometabolism, infection-induced haematopoietic stress responses, and metabolic crosstalk in cancer. Key themes include mitochondrial dynamics, metabolic adaptation, and innate immune signaling pathways like STING. His publications appear in high-impact journals such as Cell Reports , Nature Communications , and Blood . He is actively funded by major research bodies including the British Heart Foundation, The Big C Appeal, Academy of Medical Sciences, and BBSRC. While no formal scientific awards are listed in the provided text, his research has led to clinical trials involving BTK inhibitors in myeloma patients. Professor Rushworth mentors several PhD researchers, including Dominic Fowler-Shorten, E. E. Wojtowicz, A. Jibril, J. A. Moore, and J. Mistry. He leads the Rushworth Group, which is part of the Metabolic Health Research Centre at UEA, focusing on metabolic processes in the tumour microenvironment.

• Molecular Haematology
• Cancer Metabolism
• Tumour Microenvironment
• +۱۲ مورد دیگر

Professor Bertie Göttgens is Director of the Cambridge Stem Cell Institute and holds the Chair of Molecular Haematology at the University of Cambridge. He leads a research group focusing on cellular decision-making in blood stem cells and leukaemia. His work integrates experimental and computational approaches, with key contributions to understanding blood development and leukaemia pathogenesis. Current research emphasizes stem cell differentiation dynamics, leukaemogenic mutations, and computational models of haematopoiesis. Education: DPhil in Biological Sciences from the University of Oxford (1994). Postdoc at the University of Cambridge (1994–2001). Subsequent roles included Leukaemia Research Fund Lecturer (2002–2007) and Reader in Haematology (2007–2011) before becoming full Professor in 2011. Research Interests: Mechanisms regulating blood stem cell function Functional consequences of leukaemogenic mutations Single-cell genomics and computational modelling of haematopoiesis Early blood development and progenitor cell differentiation Grants & Funding: Supported by MRC, Wellcome Trust, Blood Cancer UK, Cancer Research UK, NIH, and the Aging Biology Foundation. Over 40 publications in high-impact journals like Cell Stem Cell , Nature , and Nature Cell Biology . Labs/Teams: Directs the Göttgens Group at the Jeffrey Cheah Biomedical Centre, comprising 15+ researchers including PhD students and postdocs. Key lab members include Hiromitsu Harimoto, Tomoya Isobe, and Luke Harland.

• Molecular Haematology
• Blood Stem Cell Biology
• Leukaemia
• +۴ مورد دیگر

Professor Patrick Kennedy is a Clinical Professor of Translational Hepatology at the Faculty of Medicine and Dentistry , Queen Mary University of London (QMUL), and a Consultant Hepatologist at Barts Health NHS Trust. His research focuses on the translational aspects of Hepatitis B virus (HBV) infection, particularly in young adults, and he leads the dedicated young adult liver service at The Royal London Hospital. Research Themes : Redefining disease phases in Chronic Hepatitis B (CHB), age-related immune responses, treatment endpoints in CHB, and immune-mediated liver injury mechanisms. Collaborations : Works with national institutions like UCL, Imperial College London, and international partners such as Duke-NUS Medical School (Singapore) and University of Rome Tor Vergata (Italy). Teaching : Chairs the MSc in Gastroenterology program and contributes to undergraduate MBBS teaching, including bedside clinical instruction and virology modules.

• Viral Hepatitis
• Translational Hepatology
• Immunology
• +۹ مورد دیگر

Rebecca Garnham is a Lecturer in Cancer Biology at the University of Sunderland's School of Medicine, where she teaches in the MBChB Medicine program. She maintains guest researcher status at Newcastle University and actively collaborates with their research teams on prostate cancer projects. Dr. Garnham completed her Biomedical Science degree with distinction at the University of Sunderland in 2018, which sparked her interest in cancer research. She then pursued an MRes in Cancer at Newcastle University, followed by a PhD in prostate cancer glycoimmunology, investigating sialoglycan-Siglec interactions within the prostate cancer tumor immune microenvironment. After her PhD, she worked as a Post Doctoral Research Associate before joining the University of Sunderland as a Lecturer. Her research focuses on the critical interplay between immunoinhibitory receptors (Siglecs) on immune cells and sialic acid hyper-expressed on tumor cells, with the goal of targeting this interaction to improve cancer treatment responses. Her work spans cancer immunology, prostate cancer biology, immunotherapies, and glycobiology, with particular expertise in how glycosylation patterns affect tumor immunity and progression. Dr. Garnham's publication record demonstrates consistent progress in understanding glycosylation enzymes and their role in prostate cancer. Her recent work has revealed how sialic acid blockade inhibits metastasis to bone, how ST3Gal1 synthesis of Siglec ligands mediates anti-tumor immunity, and how various glycosylation enzymes like ST6GAL1 and GALNT7 promote cancer progression through aberrant sialylation and O-glycosylation. Sialic acid blockade inhibits prostate cancer metastasis to bone (2024) ST3Gal1 synthesis of Siglec ligands mediates anti-tumor immunity (2024) GCNT1 mediated O-glycosylation in aggressive prostate cancer (2023) ST6GAL1-mediated aberrant sialylation promotes prostate cancer progression (2023) CDC20 regulation by KMT5A in castration-resistant prostate cancer (2023) Dr. Garnham continues to work closely with Newcastle University on research projects and actively seeks self-funded PhD and summer project students interested in investigating sialic acid-Siglec interactions within the prostate cancer tumor immune microenvironment or developing strategies to target these interactions to improve response rates to cancer immunotherapy.

• Cancer Biology
• Cancer Immunology
• Prostate Cancer
• +۲ مورد دیگر

Dr. Michele Zagnoni is a Reader (equivalent to Associate Professor) in the Department of Electronic & Electrical Engineering at the University of Strathclyde, Glasgow, UK. He leads the Zagnoni Lab, which focuses on developing microfluidic and lab-on-a-chip technologies for healthcare applications including fundamental biological research, drug screening, and personalized medicine therapy. His research group works on creating organ-on-a-chip in vitro models and synthetic biology applications. His academic qualifications include: Ph.D. degree in Electronic Engineering and Computer Science (2006) Dr. Eng. degree (5 year degree) in Electronic Engineering with Bioengineering qualification (2002) Italian state certification for engineering practice (2002) PostGraduate Certificate in Advanced Academic Studies (2012) Member of the EPSRC Peer Review College (2013) Dr. Zagnoni's research spans microfluidic technology development for healthcare applications with particular emphasis on: Development of microsystems for basic biology investigation Diagnosis and treatment of disease Creation of in vitro models and organ-on-a-chip systems Synthetic biology applications High-throughput screening and diagnostic systems His recent publications (2020-2025) demonstrate a strong trend toward neurological disease modeling, cancer research, and reproductive health applications using microfluidic platforms. His work bridges fundamental microfluidic technology development with applied healthcare solutions, with increasing focus on patient-derived models and precision medicine approaches for conditions including Parkinson's disease, Alzheimer's disease, cancer, and stroke. Scientific recognition includes: Member of Departmental Safety Committee (2011) Dr. Zagnoni actively supervises students and has secured numerous research grants, including major projects funded by EPSRC and the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs). His lab has developed innovative microfluidic platforms for drug screening, disease modeling, and diagnostic applications. Current research projects include developing human stroke-on-a-chip models, engineering the bone marrow niche to control stem cell regulation, and creating microfluidic platforms for immuno-oncology drug screening services. The Zagnoni Lab operates from the Technology and Innovation Centre at the University of Strathclyde and collaborates extensively with biotech and pharmaceutical industries. The lab has also spun out ScreenIn3D, a start-up company providing miniaturized oncology drug screening services using 3D human in vitro models of disease.

• Microfluidics
• Lab-on-a-chip
• Bioelectronics
• +۴ مورد دیگر